Delving Into Seattle Genetics, Inc. (SGEN)’s Upcoming Readout
Seattle Genetics, Inc. (NASDAQ:SGEN) just reported second quarter financials, and the company is up nearly 10% on the data.
Posts Tagged ‘NASDAQ:SGEN’
Stumbling Biotech Stocks Spell Doom for Baker Bros. Advisors
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused hedge fund Baker Bros...
Seattle Genetics Inc (SGEN): Baker Bros. Keeps Buying Shares
Seattle Genetics Inc. (NASDAQ:SGEN) is the subject of a new 13D filing issued by Julian Baker and Felix Baker‘s Baker Bros. Advisors.
Healthcare-focused Baker Bros. Advisors’ Top Picks: Incyte, Alexion, ACADIA & More
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
13D Filing: Baker Bros. Advisors Buys More Shares of Seattle Genetics Inc (SGEN)
Seattle Genetics Inc. (NASDAQ:SGEN) is the subject of a new 13D filing issued by Julian Baker and Felix Baker's Baker Bros.
Billionaire Christian Leone Boosts Stake in This TV Station Operator, Nelson Peltz Lifts Stake in Struggling Pentair plc. (PNR), Plus 2 Other Moves
Fresh statistics reveal that the 50 most popular stocks among hedge funds lost 10% in 2015, which practically means that individual investors should have avoided to invest in...
The Smart Money Is Hoarding Shares of These 10 Healthcare Stocks: Part 1
Given elite hedge funds have filed their latest 13F's, we have an opportunity to analyze what hedge funds like and what they don't like.
Top 5 Healthcare Bets of World-Class Baker Bros. Advisors
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
Here is What Hedge Funds Think About Seattle Genetics, Inc. (SGEN)
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Two Healthcare-Focused Funds Buy More Shares Of 2 Promising Companies, While Activist Cashes Out Of IT Company
You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman.
Strong Insider Selling Activity Detected: Cheniere Energy Inc. (LNG) and Others
Generally, insider trading activity represents an important tool in the process of fundamental security analysis, as it can offer some insights on how insiders feel about the ...
Baker Bros. Relentlessly Adding Shares Of One Biotech, Going Activist On Another
Julian Baker and Felix Baker’s Baker Bros. Advisors continues to relentlessly add shares to its position in Seattle Genetics, Inc. (NASDAQ:SGEN).
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks
Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.
Seattle Genetics Inc. (SGEN), Cerus Corporation (CERS): Baker Bros. Advisors’ Latest Moves
Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday.
Felix Baker’s Baker Bros. Advisors Raises Positions In These Stocks
In several new filings with the Securities and Exchange Commission, Julian and Felix Bakers' healthcare-focused fund Baker Bros.
Recent Multi-Millionaire Insider Purchases: Kinder Morgan (KMI), TransDigm Group (TDG), Seattle Genetics (SGEN)
Over the past week, a few multi millionaire insider purchases caught my eye.
Baker Bros. Advisors Ups Stake in Seattle Genetics Inc. (SGEN)
Baker Bros. Advisors, managed by Julian Baker and Felix Baker, have disclosed raising its stake in Seattle Genetics Inc. (NASDAQ:SGEN). In a new filing with the U.S.
Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%
Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.
Baker Bros. Strengthens Position in Seattle Genetics, Inc. (SGEN)
Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.
Baker Bros Advisors Increases Stake in Seattle Genetics Inc (SGEN)
Julian Baker and Felix Baker are betting big on Seattle Genetics, Inc. (NASDAQ:SGEN).
Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don't only have to consider the actions of the drug on the body.
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Pfizer Inc. (PFE): Is Seattle Genetics (SGEN) an Acquisition Target?
In late August, Amgen agreed to buy Onyx Pharmaceuticals in one of the worst-kept M&A secrets of the year.
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Investors Should Brace for a Busy Week From the Biotech Sector
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Hedge Fund Bets On Onyx Pharmaceuticals, Inc. (ONXX)
As fast as we can type this, Phill Gross and Robert Atchinson's hedge fund, Adage Capital Partners, disclosed ownership of about 3.7 million shares of Onyx Pharmaceuticals, ...
Should You Avoid Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ)?
In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
What Hedge Funds Think About Medivation Inc (MDVN)
In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets.
Is Illumina, Inc. (ILMN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): This Company Has Potential to Grow
Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star performers.
Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), Onyx Pharmaceuticals, Inc. (ONXX), Seattle Genetics, Inc. (SGEN): Betting on Blockbusters
Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year.
Celldex Therapeutics, Inc. (CLDX) On The Rise
There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics, Inc.
Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Seattle Genetics, Inc. (SGEN): A Billion-Dollar Anticancer Technology in the Making
Anticancer drugs typically damage normal cells as well as cancer cells.
ACADIA Pharmaceuticals Inc. (ACAD): Look Before You Leap With This Company
ACADIA Pharmaceuticals Inc.
Amarin Corporation plc (ADR) (AMRN): Something Fishy? Or Business as Usual?
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
ImmunoGen, Inc. (IMGN), Seattle Genetics, Inc. (SGEN), Celldex Therapeutics, Inc. (CLDX): A Trio of Cancer Immunotherapy Innovators
The cancer world has been abuzz after an exciting ASCO conference. Bristol Myers Squibb Co.
Should You Avoid Seattle Genetics, Inc. (SGEN)?
Seattle Genetics, Inc. (NASDAQ:SGEN) was in 8 hedge funds' portfolio at the end of the first quarter of 2013. SGEN has experienced a decrease in hedge fund interest lately.
ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing.
Bristol Myers Squibb Co. (BMY), Pharmacyclics, Inc. (PCYC): Hedging Against Leukemia
As I noted 11 weeks ago, cancer statistics are both staggering and disappointing.
Biogen Idec Inc. (BIIB), Pharmacyclics, Inc. (PCYC), Immunomedics, Inc. (IMMU), and Tackling Cancer, Non-Hodgkin Lymphoma’s Biggest Current & Upcoming Players
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Pharmacyclics, Inc. (PCYC), Genomic Health, Inc. (GHDX)…Mega-Hedge Fund Focusing on The Life Sciences
The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium...
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
Is Seattle Genetics, Inc. (NASDAQ:SGEN) a healthy stock for your portfolio? The smart money is in a pessimistic mood.
What Is This CEO Doing to Earn $450 Per Hour? – Geron Corporation (GERN)
The questions from analysts at the end of a company's conference call typically fall in the softball category.
This FDA Approval Is Actually a Big Deal: Dendreon Corporation (DNDN)
As we've learned in recent years, getting an approval from the Food and Drug Administration is only half the battle.
